Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer

NCT00267488 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00267488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00267488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
December 31, 2007
Enrollment
70 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, neoplasms, endometrial